Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -19.85% is 58% above its 5-year average of -47.48%, near the high end of its 5-year range (-368.50%–40.81%).
31.39% above its 12-month average of -28.93%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3.82%.
EBITDA MARGIN
-19.85%
EBITDA MARGIN AVG TTM
-28.93%
EBITDA MARGIN AVG 3Y
-46.20%
EBITDA MARGIN AVG 5Y
-47.48%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+31.39%
CURRENT VS 3Y AVG
+57.03%
CURRENT VS 5Y AVG
+58.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Biofrontera Inc.
Market Cap
$11.41M
EBITDA Margin
-19.85%
TTM Avg
-28.93%
3Y Avg
-46.20%
5Y Avg
-47.48%
Market Cap
$11.21M
EBITDA Margin
28.31%
TTM Avg
28.31%
3Y Avg
28.31%
5Y Avg
-18969.31%
Market Cap
$11.01M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
Market Cap
$11.94M
EBITDA Margin
-1.94%
TTM Avg
-1.94%
3Y Avg
-10.48%
5Y Avg
-10.95%
Market Cap
$11.95M
EBITDA Margin
-1346.05%
TTM Avg
-2835.20%
3Y Avg
-1619.25%
5Y Avg
-1619.25%
Market Cap
$10.74M
EBITDA Margin
-284.92%
TTM Avg
-261.31%
3Y Avg
-2315.78%
5Y Avg
-2461.07%
Market Cap
$12.46M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biofrontera Inc. (BFRI) | $11.41M | -19.85% | -28.93% | -46.20% | -47.48% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | 28.31% | 28.31% | 28.31% | -18969.31% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| IRIDEX Corporation (IRIX)vs › | $11.94M | -1.94% | -1.94% | -10.48% | -10.95% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | -1346.05% | -2835.20% | -1619.25% | -1619.25% |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.74M | -284.92% | -261.31% | -2315.78% | -2461.07% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -34.02% | -37.67% | -64.98% | -56.41% |
| Caring Brands, Inc. (CABR)vs › | $10.27M | -133689.80% | -133689.80% | -133689.80% | -133689.80% |
Gross Margin
84.5%
EBITDA Margin
-19.9%
Operating Margin
-21.9%
Net Margin
-13.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3.82% |
| 2026-03-31 | -40.99% |
| 2025-12-31 | 40.81% |
| 2025-09-30 | -86.88% |
| 2025-06-30 | -53.79% |
| 2025-03-31 | -50.40% |
| 2024-12-31 | -11.87% |
| 2024-09-30 | -51.58% |
| 2024-06-30 | -60.75% |
| 2024-03-31 | -65.31% |
| 2023-12-31 | -33.69% |
| 2023-09-30 | -49.11% |
| 2023-06-30 | -144.44% |
| 2023-03-31 | -59.84% |
| 2022-12-31 | -47.73% |
| 2022-09-30 | -81.17% |
| 2022-06-30 | -136.41% |
| 2022-03-31 | -30.55% |
| 2021-12-31 | -19.08% |
| 2021-09-30 | -368.50% |
| 2021-06-30 | -60.63% |
| 2021-03-31 | -71.46% |
| 2020-12-31 | -0.57% |
| 2020-09-30 | -67.74% |
| 2020-06-30 | -98.58% |
| 2020-03-31 | -78.00% |
